| Identification | Back Directory | [Name]
Unii-U2Y5ofn795 | [CAS]
649735-63-7 | [Synonyms]
CS-362
Bms582664
Bms 582664
Unii-U2Y5ofn795
Brivanib alaninate
[14C]-Brivanib alaninate
Unii-U2Y5ofn795 USP/EP/BP
Brivanib alaninate BMS-540215
Brivanib alaninate(BMS-582664)
BMS-582664;BMS 582664;BMS582664
(S)-(R)-1-((4-((5-Fluoro-2-methyl-1H-indol-6-yl)oxy)-5-methylpyrrolo-[2,1-f][1,2,4]triazin-6-y
L-Alanine (1R)-2-[[4-[(4-fluoro-2-Methyl-1H-indol-5-yloxy)]-5-Methyl-1H-pyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]isopropyl ester
(1R)-2-((4-((4-Fluoro-2-methyl-1H-indol-5-yl)oxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)oxy)-1-methylethyl L-alanine ester
L-Alanine, (1R)-2-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-5-methylpyrrolo(2,1-F)(1,2,4)triazin-6-yl)oxy)-1-methylethyl ester
(2R)-1-({4-[(4-fluoro-2-Methyl-1H-indol-5-yl)oxy]-5-Methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-yl (2S)-2-aMinopropanoate
(1R)-2-((4-((4-Fluoro-2-methyl-1H-indol-5-yl)oxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)oxy)-1-methylethyl L-alanine ester Brivanib alaninate (BMS-582664) | [Molecular Formula]
C22H24FN5O4 | [MDL Number]
MFCD28142640 | [MOL File]
649735-63-7.mol | [Molecular Weight]
441.46 |
| Chemical Properties | Back Directory | [density ]
1.42±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
≥22.05 mg/mL in DMSO; insoluble in H2O; ≥10.03 mg/mL in EtOH | [form ]
Yellow powder. | [pka]
16.08±0.30(Predicted) | [color ]
White to brown |
| Hazard Information | Back Directory | [Uses]
A novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor. | [Uses]
BMS-582664 is an oral VEGFR/FGFR inhibitor for VEGFR2, Flk1, VEGFR1 and FGFR1 with IC50 of 25 nM, 89 nM, 380 nM and 148 nM, respectively. | [Definition]
ChEBI: Brivanib alaninate is a carboxylic ester resulting from the formal condensation of the carboxy group of L-alanine with the hydroxy group of brivanib. It is a prodrug of brivanib (BMS-540215), a potent oral dual inhibitor of VEGFR-2 and FGFR-1 (IC50 of 25 nM and 148 nM, respectively) and was in development for the treatment of hepatocellular and colon carcinomas. It has a role as an antineoplastic agent, an EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor, a prodrug, an apoptosis inducer, a fibroblast growth factor receptor antagonist and an angiogenesis inhibitor. It is a pyrrolotriazine, an aromatic ether, a fluoroindole, a diether, a carboxylic ester and a L-alanine derivative. It is functionally related to a brivanib. | [target]
VEGFR2 | [storage]
Store at -20°C |
|
|